Equity · Healthcare
LTRN
Lantern Pharma Inc. · NasdaqCM
The line runs $3.31 on 27 May through $2.89 on 17 July, on a scale from $2.5 to $4.5. Days the market did not trade hold the previous close, flat.
The chart above plots the price of LTRN over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 36 sessions over that window: $3.31 on 27 May 2026 through $2.89 on 17 July 2026.
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 25, 2026
LTRN insider trades
LTRN has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 19 August 2025.
Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
LTRN reported financials
LTRN reported net income of −$17.1M for the fiscal year ended 31 Dec 2025.
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
LTRN earnings
no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
LTRN institutional holders
3 of the 45 institutional funds we track reported a LTRN position for the quarter ended 30 Jun 2026 — a combined $1.5M; the latest of those filings landed 14 Aug 2026.
Source: SEC EDGAR 13F filings
LTRN fails-to-deliver
On 22 Jul 2026, 827 shares of LTRN failed to deliver (about $2K).
Source: SEC fails-to-deliver (CNS) data